Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. METHODS: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. RESULTS: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. CONCLUSIONS: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid therapy [91].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [91]
In the citing paper
“In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [11]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Research works printed but not linked: 2
- Sambrook PN, 2001, Aust Fam Physician, 30, 793
- Mudano A, 2001, J Rheumatol, 28, 1298
Cited by
Items 801–900 of 910
Die Rolle der Wnt-Inhibitoren Sklerostin und Dickkopf-1 bei Erkrankungen des Knochens
Göbel, A., Rachner, T. D., Rauner, M., & Hofbauer, L. C. (2016) · Osteologie/Osteology · doi:10.1055/s-0037-1619017
Response to Letter to the Editor of JBMR: Treatment Sequence Matters
Cosman, F., Nieves, J. W., & Dempster, D. W. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3126
Glucocorticoid induced osteoporosis and mechanisms of intervention
Sato, A. Y. (2017) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2111
Management der Osteoporose bei entzündlich-rheumatischen Erkrankungen
Demary, W. (2017) · Aktuelle Rheumatologie · doi:10.1055/s-0042-118385
Prophylaxe und Therapie der Glukokortikoid-induzierten Osteoporose
Oelzner, P., & Wolf, G. (2017) · Aktuelle Rheumatologie · doi:10.1055/s-0042-124182
Mokuda, S. (2015) · Medical Research Archives · doi:10.18103/mra.v0i3.129
Marcus, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809969-8.00016-4
Self-citationWorkshop report Endocrine Aspects of Duchenne Muscular Dystrophy
Bianchi, M. L., Biggar, D., Bushby, K. M. D., Rogol, A. D., Rutter, M. M., & Tseng, B. S. (2011)
Osteoporosis Treatment: Bone-Forming Agents
Langdahl, B. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65349-7
Diseases of Mineral Metabolism and Bone: Emerging Therapeutics for Postmenopausal Osteoporosiss
Miller, P. D. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2745-1_9
(2013) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.s10-001
Glucocorticoid‐induced Osteoporosis
Silverman, S. L., & Venuturupalli, S. (2013) · Wiley eBooks · doi:10.1002/9781118316290.ch6
Metabolic Bone Disease in Gastrointestinal Disorders
Cranney, A., Rostom, A., Dubé, C., Mohamed, R., Tugwell, P., Wells, G. A., & McDonald, J. W. (2010) · Wiley eBooks · doi:10.1002/9781444314403.ch16
Clinical and basic research papers – November 2007 selections
Ferrari, S., Seeman, E., & Strewler, G. J. (2007) · BoneKEy-Osteovision · doi:10.1138/20070281
Metabolic Bone Disease in Gastrointestinal Disorders
Bami, H., Lau, A. N., & Adachi, J. D. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch16
Management of Bone Disorders in Kidney Disease
Sprague, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_17
Basic of Osteoporosis and the Topics
Kawaguchi, H. (2019) · リハビリテーション医学 : 日本リハビリテーション医学会誌 · doi:10.2490/jjrmc.56.349
Saag, K. G., Geusens, P., & Lems, W. F. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41013
Self-citationMoreira, C. A., Cosman, F., & Dempster, D. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11274-7
Evaluation and Medical Management of Vertebral Osteoporosis: Preventing the Next Fracture
Hant, F. N., & Bolster, M. B. (2020) · Springer eBooks · doi:10.1007/978-3-030-33861-9_4
Surgical Strategies in Osteoporotic Bone
Zavatsky, J. M., & McGuire, R. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-33861-9_18
Cusano, N. E., Silverberg, S. J., & Bilezikian, J. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00204-7
Osteoporosis - 2nd part, pharmacotherapy
Matalová, P. (2019) · Interní medicína pro praxi · doi:10.36290/int.2019.039
Teriparatide and abaloparatide treatment for osteoporosis
Cosman, F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00076-9
Osteoporosis associated with eating disorders
Robinson, L., & Misra, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00044-7
Glucocorticoid-induced osteoporosis and Cushing’s syndrome
Saag, K. G., Adler, R. A., & Weinstein, R. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00045-9 · Cited by 1
Self-citationDiagnosis and Treatment of Osteoporosis in CKD
Damasiewicz, M. J., & Nickolas, T. L. (2020) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2020.19.3.6
Aspekte der medikamentösen Therapie der Osteoporose bei rheumatoider Arthritis
Buehring, B., Thomasius, F. E., & Maus, U. M. (2021) · Arthritis und Rheuma · doi:10.1055/a-1365-0418
Jakob, F. J., Oertel, H., Langdahl, B. L., Ljunggren, Ö., Barrett, A., Karras, D., Walsh, J. B., Fahrleitner‐Pammer, A., Rajzbaum, G., Barker, C., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0740e
Mahmoud, M. E.-S. (2021) · Clinical and Experimental Pharmacology
Suzuki, A., Okano, T., & Nakamura, H. (2021) · The Spine Journal · doi:10.1016/j.spinee.2021.01.013
골다공증 치료의 최신 지견: 누구를, 무엇으로, 얼마 동안 치료할 것인가?
Kim, S. (2013) · Korean Journal of Medicine
Side Effects of Long - Term Glucocorticoid Therapy: Case Report
Lebada, I. C., Măerean, E. T., & Inţă, R.-F. (2021) · Acta Medica Transilvanica · doi:10.2478/amtsb-2021-0027 · Cited by 2
Мазур, І. П., Gumeniuk, М., Іgnatieva, V. І., Lynnyk, М. І., Kharchenko-Sevriukova, G. S., & Kuts, V. V. (2014)
The Utility and Applicability of Risk Assessment Tools and Trabecular Bone Score
Silva, B. C. C., & Soares, M. M. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-83951-2_3
Cusano, N. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-83951-2_13
The Value of Trabecular Bone Score in Patients with Rheumatic Diseases
Kolpakov, K. I., Korolev, M. A., & Ubshaeva, Y. B. (2021) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn1542
Takahata, M., Shimizu, T., Yamada, S., Yamamoto, T., Hasegawa, T., Fujita, R., Kobayashi, H., Endo, T., Koike, Y., Amizuka, N., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1075694/v1
Bone Disease in Renal Transplantation
West, B. L., Sprague, S. M., & Josephson, M. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1690-7_19
Principles and Guidelines of Immunotherapy in Neuromuscular Disorders
Mitchell, C. W., & Bertorini, T. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00007-x
Glucocorticoids and Musculoskeletal Health
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_31
Deal, C. L., & Abelson, A. G. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00197-4 · Cited by 1
(2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328334b3e8
Northcott, M., & Morand, E. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820583-9.00006-3 · Cited by 1
Osteoporosis associated with rheumatologic disorders
Dubrovsky, A., Goldring, S. R., & Lane, N. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00053-8
Eriksen, E. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-23639-1_3
Current awareness: Pharmacoepidemiology and drug safety
(2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1486
Glucocorticoid-Induced Osteoporosis
Lewiecki, E. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_26
Gennari, L., Bandeira, L., Costa, A. G., Cusano, N. E., Silva, B. C. C., & Bilezikian, J. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_25 · Cited by 1
Cusano, N. E., Silverberg, S. J., & Bilezikian, J. P. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00200-1
Veränderungen von Knochendichte und Knochenstruktur (M 80–M 85)
Braun, J., Felsenberg, D., & Minne, H. W. (2008) · Springer eBooks · doi:10.1007/978-3-540-34105-5_70
Geriatric pharmacotherapy updates
Guay, D. R. P. (2008) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2008.03.002
Kim, S., Munshi, L. B., Alamoush, B., Zaidi, M., & Epstein, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11237-1
Osteoporosis en atención primaria
(2011) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(11)70214-6
(2018) · Elsevier eBooks · doi:10.1016/b978-3-437-22102-6.00005-6
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00024-8
Parathyroid Hormone Treatment for Osteoporosis
Cosman, F., & Greenspan, S. L. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch51
An inconvenient status in anti-osteoporotic treatment process: corticosteroid use
Öztürk, E., Çiğiloğlu, A., Çakmak, G., & Öztürk, Z. A. (2022) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20211368
Concerns on Medications Used in Osteoporosis
Li‐Yu, J. (2022) · Journal of Clinical Rheumatology and Immunology · doi:10.1142/s2661341722300063
Torres, M. M., Martín, A. G., Bolívar, V. C., & Sevilla, J. E. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.06.011
Mechanism and efficacy of parathyroid hormone in osteoporosis
Kim, S. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.6.361
Traitements médicamenteux préventifs des ostéoporoses
Nachef, C., & Roux, C. (2022) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2022.07.002
Iki, M., Fujimori, K., Nakatoh, S., Tamaki, J., Ishii, S., Okimoto, N., Kamiya, K., & Ogawa, S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4136034
Medikamenteninduzierte Osteopathien in der Rheumatologie
Fiehn, C., & Bauhammer, J. (2022) · Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen · doi:10.1007/s41970-022-00212-x
Condiciones especiales en enfermedades reumáticas
Ortiz, B. O. A. (2021) · CID - Centro de Investigación y Desarrollo eBooks · doi:10.37811/cl_w798
Part II : Interactive case: Drug‐induced endocrine disorders
Donihi, A. C. (2023) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1813 · Cited by 1
Terapia anabolica dell’osteoporosi nel 2023
Ciafardini, A., Jaafar, S., & Mazziotti, G. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01348-w
Denosumab: Clinical Applications, Outcomes, and Perspectives in Osteoporosis
Eshak, N., Rimu, A. H., & Hoffman, A. (2023) · Tissue repair and reconstruction · doi:10.1007/978-981-99-5826-9_2
Chalem, M., Casas, N., Domínguez, A. M., Fernández, D. G., González, A., Jauregui, E. A., Molina, J. F., Rincón, D. N., Gutiérrez, C. E. T., Grajales, F. J. V., et al. (2023) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2023.06.003 · Cited by 1
Drug Therapeutics of Osteoporosis, Vertebral Fracture and Nonunion
Gou, P., & Chang, F. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003130
Geriatric trauma: there is more to it than just the implant!
Lee, C., Kates, S. L., Graves, M. L., Jeray, K. J., Javedan, H., Firoozabadi, R., & Schemitsch, E. H. (2024) · OTA International The Open Access Journal of Orthopaedic Trauma · doi:10.1097/oi9.0000000000000327
Drug holiday effect on osteoporosis: a narrative review of the current literature
Velitsikakis, P.-A., Psochias, P., Kopanos, S., Perisynakis, N., & Giovanidis, G. (2024) · The Egyptian Orthopaedic Journal · doi:10.4103/eoj.eoj_141_23 · Cited by 1
Osteoporosis treatment: Bone-forming agents
Langdahl, B. L., Mäkinen, V.-N., & Sølling, A. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00053-4
Prync, A. E. S., Bagnato, J., Olano, L., Rivara, J. P. R., Ligo, M. F. S., Torrens, P., & Carlucci, A. M. (2023) · Revista Bioquímica y Patología Clínica · doi:10.62073/bypc.v87i1.181 · Cited by 1
Jallali, T., Reiser, E., & Tóth, B. (2024) · Gynäkologie in der Praxis · doi:10.1007/s41974-024-00343-9
Incidence, prevalence, and predictors of osteoporotic fracture in adult lung transplant recipients
Ng, E., Kumar, S., Paul, E. M., Bennett, D., Rosi, L., Fuller, L., Chiu, L., Sztal‐Mazer, S., Ivulich, S. P., Snell, G. I., et al. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100182
Osteoporosis: how to diagnose and what treatment to prescribe
Toroptsova, N. V., & Dobrovolskaya, O. V. (2024) · Medical alphabet · doi:10.33667/2078-5631-2024-29-40-45
Progress in the Treatment of Osteoporosis
伯, 伟. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151065
McCarrison, S., Abdelrahman, S., Quinlivan, R. C. M., Keen, R. W., & Wong, S. C. (2025) · Bone · doi:10.1016/j.bone.2025.117410 · Cited by 2
Cardiovascular effects of bone-active medications across the clinical spectrum
Rodríguez, A. J., & Ebeling, P. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00160-6
Ostéoporose : pourquoi quand et avec quel(s) médicament(s) traiter ? Comment la prévenir ?
Belkhir, R. (2025) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2025.04.001
Kaneko, K., Kaburaki, M., Muraoka, S., Shikano, K., Tanaka, N., Kawazoe, M., Kawai, S., & Nanki, T. (2025) · Cureus · doi:10.7759/cureus.82471
Wang, K., Yang, S., Ren, L., He, C., & Jia, C. (2025) · Physiotherapy Research International · doi:10.1002/pri.70097
Sheth, N. P., Krohn, K., Torkelson, J., Winzenrieth, R., Humbert, L., Pearman, L., Wang, Y., Boxberger, J. I., & Bostrom, M. P. (2025) · Bone Reports · doi:10.1016/j.bonr.2025.101858
Scharla, S. H. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21184-3.00009-0
Tsourdi, E. A., Baschant, U., Rauner, M., Taipaleenmäki, H., & Winter, E. M. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01269-3
Kong, M., Gao, C., Luan, X., Fan, C., Hao, M., Jin, C., Zhao, J., Li, H., Zhao, J., Luan, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26676566
Rosario, M. P. D., Ong-Ramos, C., & Panopio, N. J. (2025) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.369506336b
Cui, C., Chung, Y. L., Wong, H. Y., Wong, P. Y., Liu, C., Zhang, N., Cheung, W. H., & Wong, R. M. Y. (2026) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.10.012 · Cited by 1
Osteoporosis Update: Personalized Risk Assessment and Treatment
Sung, N., Novik, R., Cohn, M., & Batur, P. (2026) · Journal of Women s Health · doi:10.1177/15409996261421435
Payer, J., Tomková, S., Killinger, Z., Brázdilová, K., Jackuliak, P., Vaňuga, P., Letkovská, A., Masaryk, P., Kmečová, Z., & Kužma, M. (2018) · Clinical Osteology · doi:10.36290/clo.2018.019 · Cited by 2
Postmenopausal osteoporosis: standard diagnostic and therapeutic practice
Payer, J., Killinger, Z., Jackuliak, P., & Kužma, M. (2018) · Clinical Osteology · doi:10.36290/clo.2018.005 · Cited by 3
Zikán, V. (2022) · Clinical Osteology · doi:10.36290/clo.2022.018
Osteoporose induzida por glicocorticoide (OPIG)
da Silva, A. R. B. (2025) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2025.24.3.29-39
Management of glucocorticoid-induced osteoporosis in rheumatic diseases
Shrestha, P., Popuri, S. B., Hoffer, C., Qureshi, A., Barzilay, J. I., Dapaah, E. A., & Carbone, L. D. (2026) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2026.102151 · Cited by 2
Herath, M., Nguyen, H. H., Milat, F., & Ebeling, P. R. (2026) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjag088
Valokola, M. G., Ahmadi, F., Bayat, R., Haeri, S. M. J., Fallahnezhad, S., & Sahebkar, A. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00503-z
Calcium and Vitamin D Supplements in Patients With Sarcoidosis
Ungprasert, P., Keller, S. F., & Culver, D. A. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.05.032
Metadata
- Authors
- Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R.
- Affiliations
- University of Alabama at Birmingham (US)
- Columbia University (US)
- KU Leuven (BE)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2028-2039
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042007405
- Cited by
- 914
- References
- 40
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 36 · 2023: 32 · 2022: 45 · 2021: 56 · 2020: 43 · 2019: 38 · 2018: 53 · 2017: 35 · 2016: 33 · 2015: 51 · 2014: 49 · 2013: 59 · 2012: 61
- FWCI
- 63.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- teriparatide, alendronate, glucocorticoid-induced osteoporosis, bisphosphonates, bone mineral density, vertebral fractures, non-vertebral fractures, fracture risk, serum calcium, bone turnover markers, anabolic therapy
- MeSH terms
- Aged, Aged, 80 and over, Calcium, Double-Blind Method, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Risk, Biomarkers, Bone Density, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.